Radiosynthesis of no-carrier-added meta-[124I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma

Michael Green; Jonathan Lowe; Manikandan Kadirvel; Adam McMahon; Nigel Westwood; Sue Chua; Gavin Brown

doi:10.1007/s10967-016-5073-1

Radiosynthesis of no-carrier-added meta-[¹²⁴I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma

Michael Green, Jonathan Lowe, Manikandan Kadirvel^*, Adam McMahon, Nigel Westwood, Sue Chua, Gavin Brown

^*Corresponding author for this work

Chemical Engineering

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

15 Downloads (Pure)

Abstract

Meta-iodobenzylguanidine (mIBG) has been radiolabelled at the no-carrier-added level with [¹²⁴I] for a proof of concept study to assess the diagnostic accuracy of [¹²⁴I]mIBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of mIBG was achieved via the iododesilylation reaction between [¹²⁴I]sodium iodide and meta-trimethylsilylbenzylguanidine. [¹²⁴I]mIBG was produced in 62–70 % radioiodide incorporation yield from [¹²⁴I]sodium iodide. The average amount of formulated [¹²⁴I]mIBG was 359 MBq (range 344–389 MBq) with an average specific radioactivity of 4.1 TBq μmol⁻¹ (range 1.8–5.9 TBq μmol⁻¹) at end of synthesis.

Original language	English
Pages (from-to)	727-732
Number of pages	6
Journal	Journal of Radioanalytical and Nuclear Chemistry
Volume	311
Issue number	1
Early online date	24 Oct 2016
DOIs	https://doi.org/10.1007/s10967-016-5073-1
Publication status	Published - Jan 2017

Bibliographical note

Funding Information:
This work was supported by Cancer Research UK Grant A15107 and Rising Tide. The author (SC) acknowledges financial support from the Department of Health via the National Institute for Health Research (NIHR) and EPSRC in association with the MRC and DoH (England).

Publisher Copyright:
© 2016, The Author(s).

Keywords

Meta-iodobenzylguanidine
mIBG
Neuroblastoma
Positron emission tomography
Radiochemistry
[I]

ASJC Scopus subject areas

Analytical Chemistry
Nuclear Energy and Engineering
Radiology Nuclear Medicine and imaging
Pollution
Spectroscopy
Public Health, Environmental and Occupational Health
Health, Toxicology and Mutagenesis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10967-016-5073-1Licence: Creative Commons: Attribution (CC BY)

GreenM2017RadiosynthesisFinal published version, 527 KBLicence: Creative Commons: Attribution (CC BY)

Cite this

@article{0865032b6c604aed882bb9d189f6e4d5,

title = "Radiosynthesis of no-carrier-added meta-[124I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma",

abstract = "Meta-iodobenzylguanidine (mIBG) has been radiolabelled at the no-carrier-added level with [124I] for a proof of concept study to assess the diagnostic accuracy of [124I]mIBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of mIBG was achieved via the iododesilylation reaction between [124I]sodium iodide and meta-trimethylsilylbenzylguanidine. [124I]mIBG was produced in 62–70 % radioiodide incorporation yield from [124I]sodium iodide. The average amount of formulated [124I]mIBG was 359 MBq (range 344–389 MBq) with an average specific radioactivity of 4.1 TBq μmol−1 (range 1.8–5.9 TBq μmol−1) at end of synthesis.",

keywords = "Meta-iodobenzylguanidine, mIBG, Neuroblastoma, Positron emission tomography, Radiochemistry, [I]",

author = "Michael Green and Jonathan Lowe and Manikandan Kadirvel and Adam McMahon and Nigel Westwood and Sue Chua and Gavin Brown",

note = "Funding Information: This work was supported by Cancer Research UK Grant A15107 and Rising Tide. The author (SC) acknowledges financial support from the Department of Health via the National Institute for Health Research (NIHR) and EPSRC in association with the MRC and DoH (England). Publisher Copyright: {\textcopyright} 2016, The Author(s).",

year = "2017",

month = jan,

doi = "10.1007/s10967-016-5073-1",

language = "English",

volume = "311",

pages = "727--732",

journal = "Journal of Radioanalytical and Nuclear Chemistry",

issn = "0236-5731",

publisher = "Akad{\'e}miai Kiad{\'o}",

number = "1",

}

TY - JOUR

T1 - Radiosynthesis of no-carrier-added meta-[124I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma

AU - Green, Michael

AU - Lowe, Jonathan

AU - Kadirvel, Manikandan

AU - McMahon, Adam

AU - Westwood, Nigel

AU - Chua, Sue

AU - Brown, Gavin

N1 - Funding Information: This work was supported by Cancer Research UK Grant A15107 and Rising Tide. The author (SC) acknowledges financial support from the Department of Health via the National Institute for Health Research (NIHR) and EPSRC in association with the MRC and DoH (England). Publisher Copyright: © 2016, The Author(s).

PY - 2017/1

Y1 - 2017/1

N2 - Meta-iodobenzylguanidine (mIBG) has been radiolabelled at the no-carrier-added level with [124I] for a proof of concept study to assess the diagnostic accuracy of [124I]mIBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of mIBG was achieved via the iododesilylation reaction between [124I]sodium iodide and meta-trimethylsilylbenzylguanidine. [124I]mIBG was produced in 62–70 % radioiodide incorporation yield from [124I]sodium iodide. The average amount of formulated [124I]mIBG was 359 MBq (range 344–389 MBq) with an average specific radioactivity of 4.1 TBq μmol−1 (range 1.8–5.9 TBq μmol−1) at end of synthesis.

AB - Meta-iodobenzylguanidine (mIBG) has been radiolabelled at the no-carrier-added level with [124I] for a proof of concept study to assess the diagnostic accuracy of [124I]mIBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of mIBG was achieved via the iododesilylation reaction between [124I]sodium iodide and meta-trimethylsilylbenzylguanidine. [124I]mIBG was produced in 62–70 % radioiodide incorporation yield from [124I]sodium iodide. The average amount of formulated [124I]mIBG was 359 MBq (range 344–389 MBq) with an average specific radioactivity of 4.1 TBq μmol−1 (range 1.8–5.9 TBq μmol−1) at end of synthesis.

KW - Meta-iodobenzylguanidine

KW - mIBG

KW - Neuroblastoma

KW - Positron emission tomography

KW - Radiochemistry

KW - [I]

UR - http://www.scopus.com/inward/record.url?scp=84992198064&partnerID=8YFLogxK

U2 - 10.1007/s10967-016-5073-1

DO - 10.1007/s10967-016-5073-1

M3 - Article

AN - SCOPUS:84992198064

SN - 0236-5731

VL - 311

SP - 727

EP - 732

JO - Journal of Radioanalytical and Nuclear Chemistry

JF - Journal of Radioanalytical and Nuclear Chemistry

IS - 1

ER -